Article Text

Download PDFPDF
Randomised control trial
Non-toxigenic Clostridium difficile to prevent recurrent C. difficile infection
  1. Daniel M Musher,
  2. Hoonmo Koo
  1. Baylor College of Medicine, Houston, Texas, USA
  1. Correspondence to : Dr Daniel M Musher, Department of Infectious Diseases, VA Medical Center, 2002 Holcombe Boulevard, Houston, TX 77030, USA; Daniel.musher{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed


Clostridium difficile colitis (CDI) is strongly associated with hospitalisation and antibiotic therapy. As disruption of the colonic biome is responsible for disease, it should not be surprising that antimicrobial therapy, which further perturbs intestinal microbiota, has been such a dismal treatment failure. Treating patients for CDI with metronidazole, oral vancomycin, nitazoxanide or fidaxomycin cures a little over one-half, suppresses the disease followed by relapse in about 30% and fails to bring about a satisfactory response in about 20% of cases.1


Gerding and colleagues wanted to see whether they could successfully colonise the bowel with a non-toxin producing C. difficile (NTPCD) strain and if it could …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.